Lergotrile in the treatment of parkinsonism.

Abstract

Lergotrile mesylate, a direct-acting dopamine agonist, was administered for up to 10 months to 25 patients with Parkinson disease. Of six patients not receiving levodopa concurrently, five showed definite improvement in parkinsonian signs and symptoms. These results are the first clear indication that lergotrile is efficacious, independently of any interaction with levodopa, in the treatment of Parkinson disease. The drug was also effective in relieving some complications of long-term levodopa therapy. Lergotrile was more effective in alleviating on-off problems than in reversing loss of levodopa efficacy. Side effects of lergotrile included exacerbation of hallucinations, dyskinesias, hypotension, and alterations in liver function tests.

• Authors: H L Klawans, C G Goetz, P Volkman, P A Nausieda, W J Weiner
• Journal: Neurology (Neurology) Vol. 28 Issue 7 Pg. 699-702 (Jul 1978) ISSN: 0028-3878 [Print] United States
• PMID: 566868 (Publication Type: Journal Article)

Chemical References

• Acetonitriles
• Ergolines

Topics

• Acetonitriles (adverse effects, therapeutic use)
• Drug Evaluation
• Ergolines (adverse effects, therapeutic use)
• Humans
• Liver Function Tests
• Parkinson Disease (drug therapy)